Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 638-648

  Huillard, Olivier ^a   Bakalian, Silvin ^a   Levy, Christine ^a   Desjardins, Laurence ^a   Lumbroso Le Rouic, Livia ^a   Pop, Simona ^a   Sablin, Marie Paule ^a   Le Tourneau, Christophe ^a  

^a INSTITUT CURIE   (France)

Author keywords

Eye; Molecularly targeted agents; Ophthalmology; Systematic review; Toxicity; Treatment outcome

Indexed keywords

AFATINIB; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; DABRAFENIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TRAMETINIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB;

ANISOCORIA; CATARACT; CONJUNCTIVA; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA OPACITY; DIPLOPIA; DISEASE SEVERITY; EPISCLERITIS; EYE TOXICITY; GLAUCOMA; HUMAN; KERATOPATHY; MIOSIS; MOLECULARLY TARGETED THERAPY; ONCOLOGIST; OPHTHALMOLOGIST; PRIORITY JOURNAL; PTOSIS; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; SCLERITIS; SOLID TUMOR; SYSTEMATIC REVIEW; TRICHIASIS; VISUAL DISORDER; VISUAL FIELD DEFECT;

EYE; MOLECULARLY TARGETED AGENTS; OPHTHALMOLOGY; SYSTEMATIC REVIEW; TOXICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; EYE DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84893664963     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.016     Document Type: Review

References (56)

1. C. Robert, J.C. Soria, A. Spatz, A. Le Cesne, D. Malka, and P. Pautier et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncol 6 7 2005 491 500
2. E.L. Strevel, D.J. Ing, and L.L. Siu Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 22 2007 3362 3371
3. M.L. Telli, S.A. Hunt, R.W. Carlson, and A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 23 2007 3525 3533
4. R.J. Kelly, B. Billemont, and O. Rixe Renal toxicity of targeted therapies Target Oncol 4 2 2009 121 133
5. H. Izzedine, S. Ederhy, F. Goldwasser, J.C. Soria, G. Milano, and A. Cohen et al. Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol: Off J Eur Soc Med Oncol/ESMO 20 5 2009 807 815
6. V.C. Sheffield, and E.M. Stone Genomics and the eye N Engl J Med 364 20 2011 1932 1942
7. T. al-Tweigeri, J.M. Nabholtz, and J.R. Mackey Ocular toxicity and cancer chemotherapy. A review Cancer 78 7 1996 1359 1373
8. K.E. Schmid, G.V. Kornek, W. Scheithauer, and S. Binder Update on ocular complications of systemic cancer chemotherapy Surv Ophthalmol 51 1 2006 19 40
9. A. Chan, C. Su, R.H. de Boer, and A. Gajdatsy Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy J Clin Oncol 31 17 2013 2123 2127
10. R. van der Noll, S. Leijen, G.H. Neuteboom, J.H. Beijnen, and J.H. Schellens Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities Cancer Treat Rev 39 6 2013 664 672
11. D.J. Renouf, J.P. Velazquez-Martin, R. Simpson, L.L. Siu, and P.L. Bedard Ocular toxicity of targeted therapies J Clin Oncol 30 26 2012 3277 3286
12. W.L. Ho, H. Wong, and T. Yau The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 91 7 2013 604 609
13. C. Le Tourneau, A. Stathis, L. Vidal, M.J. Moore, and L.L. Siu Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials J Clin Oncol 28 8 2010 1401 1407
14. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
15. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 2005 123 132
16. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
17. M.H. Kulke, H.J. Lenz, N.J. Meropol, J. Posey, D.P. Ryan, and J. Picus et al. Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 20 2008 3403 3410
18. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, and M. Tubiana-Hulin et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 2005 4265 4274
19. A.M. Wardley, X. Pivot, F. Morales-Vasquez, L.M. Zetina, M. de Fatima Dias Gaui, and D.O. Reyes et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer J Clin Oncol 28 6 2010 976 983
20. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 2012 107 114
21. K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, and J.A. Sosman et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 4 2013 482 489
22. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, and R.G. Maki et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 18 2010 1693 1703
23. J. Bauman, C. Verschraegen, S. Belinsky, C. Muller, T. Rutledge, and M. Fekrazad et al. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies Cancer Chemother. Pharmacol. 69 2 2012 547 554
24. H. Yoshioka, K. Hotta, K. Kiura, N. Takigawa, H. Hayashi, and S. Harita et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705 J Thorac Oncol 5 1 2010 99 104
25. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 12 2003 2237 2246
26. M. Ranson, L.A. Hammond, D. Ferry, M. Kris, A. Tullo, and P.I. Murray et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 9 2002 2240 2250
27. J.R. Hecht, A. Patnaik, J. Berlin, A. Venook, I. Malik, and S. Tchekmedyian et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer 110 5 2007 980 988
28. M. Untch, M. Rezai, S. Loibl, P.A. Fasching, J. Huober, and H. Tesch et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 12 2010 2024 2031
29. T. Kanda, T. Nishida, N. Wada, O. Kobayashi, M. Yamamoto, and A. Sawaki et al. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients Int J Clin Oncol 18 1 2013 38 45
30. T. Nishida, K. Shirao, A. Sawaki, M. Koseki, T. Okamura, and A. Ohtsu et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) Int J Clin Oncol 13 3 2008 244 251
31. A. Sawaki, K. Yamao, T. Nakamura, T. Suzuki, K. Okubo, and K. Hara et al. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients J Gastroenterol 39 4 2004 329 333
32. A.T. van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, and S. Dimitrijevic et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 9291 2001 1421 1423
33. V.P. Moran, R.G. Baute, J.C. Facundo, P.H. Ramirez, A.A. Nunez, and E.E. Martinez et al. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba MEDICC Rev 13 1 2011 35 40
34. J. Verweij, A. van Oosterom, J.Y. Blay, I. Judson, S. Rodenhuis, and W. van der Graaf et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 14 2003 2006 2011
35. D. O'Mahony, J.C. Morris, C. Quinn, W. Gao, W.H. Wilson, and B. Gause et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res: Off J Am Assoc Cancer Res 13 3 2007 958 964
36. A.V. Maker, G.Q. Phan, P. Attia, J.C. Yang, R.M. Sherry, and S.L. Topalian et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 12 2005 1005 1016
37. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, and C. Becerra et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 8 2012 773 781
38. J. Ahn, W.R. Wee, J.H. Lee, and J.Y. Hyon Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer Korean J Ophthalmol 25 5 2011 355 357
39. S. Yeh, H.A. Fine, and J.A. Smith Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma Cornea 28 6 2009 699 702
40. A. Shahrokni, J. Matuszczak, M.R. Rajebi, and M.W. Saif Erlotinib-induced episcleritis in a patient with pancreatic cancer JOP 9 2 2008 216 219
41. M. Breccia, F. Gentilini, L. Cannella, R. Latagliata, I. Carmosino, and A. Frustaci et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib Leuk Res 32 7 2008 1022 1025
42. B. Esmaeli, R. Diba, M.A. Ahmadi, H.G. Saadati, M.M. Faustina, and T.R. Shepler et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec) Eye (Lond) 18 7 2004 760 762
43. F.W. Fraunfelder, J. Solomon, B.J. Druker, B. Esmaeli, and J. Kuyl Ocular side-effects associated with imatinib mesylate (Gleevec) J Ocul Pharmacol Ther 19 4 2003 371 375
44. I. Georgalas, C. Pavesio, and E. Ezra Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect Graefes Arch Clin Exp Ophthalmol 245 10 2007 1585 1586
45. E. Kusumi, A. Arakawa, M. Kami, D. Kato, K. Yuji, and Y. Kishi et al. Visual disturbance due to retinal edema as a complication of imatinib Leukemia 18 6 2004 1138 1139
46. I. Masood, A. Negi, and H.S. Dua Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery J Cataract Refract Surg 31 12 2005 2427 2428
47. S.I. Kwon, D.H. Lee, and Y.J. Kim Optic disc edema as a possible complication of Imatinib mesylate (Gleevec) Jpn J Ophthalmol 52 4 2008 331 333
48. L. Min, A. Vaidya, and C. Becker Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy Eur J Endocrinol 164 2 2011 303 307
49. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, and M.E. Gore et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 9 2011 763 773
50. A. Wegner, and R. Khoramnia Neurosensory retinal detachment due to sunitinib treatment Eye (Lond) 25 11 2011 1517 1518
51. M. Saleh, T. Bourcier, G. Noel, C. Speeg-Schatz, and D. Gaucher Bilateral macular ischemia and severe visual loss following trastuzumab therapy Acta Oncol 50 3 2011 477 478
52. A.B. Tullo, B. Esmaeli, P.I. Murray, E. Bristow, B.J. Forsythe, and K. Faulkner Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials Eye (Lond) 19 7 2005 729 738
53. B. Seruga, L. Sterling, L. Wang, and I.F. Tannock Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials J Clin Oncol 29 2 2011 174 185
54. H. Kawakami, K. Sugioka, K. Yonesaka, T. Satoh, Y. Shimomura, and K. Nakagawa Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis J Clin Oncol 29 23 2011 e678 e679
55. B. Esmaeli, V.G. Prieto, C.E. Butler, S.K. Kim, M.A. Ahmadi, and H.M. Kantarjian et al. Severe periorbital edema secondary to STI571 (Gleevec) Cancer 95 4 2002 881 887
56. J.S. Larson, L.K. Bergstrom, J.D. Cameron, L.A. Erickson, and T.E. Grimm Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia Arch Ophthalmol 125 7 2007 985 986